Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Preliminary phase I data presented on MLN-0128 for advanced solid malignancies

Dec. 7, 2012

First-in-patient trial data updated for PF-03084014

Dec. 7, 2012

Type I interferon receptor 1 MAb evaluated in patients with scleroderma

Dec. 7, 2012

Varenicline as a potential treatment for methamphetamine dependence

Dec. 7, 2012

BGP-15 shows promising prophylactic and therapeutic effect in collagen-induced arthritis

Dec. 5, 2012

EZN-2208, a pegylated drug conjugate for brain tumors

Dec. 5, 2012

Rapid antidepressant effects seen for AZD-6765 in patients

Dec. 4, 2012

Phase I data presented for PF-04449913 in advanced solid tumors

Dec. 4, 2012

Favorable safety observed for BI-853520 in phase I study

Dec. 4, 2012

Dual PI3K/mTOR inhibitors prove active in glioblastoma cells

Dec. 4, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...